Your browser is no longer supported. Please, upgrade your browser.
We’ve redesigned our maps and bubbles! Read more about the new features here. ×
Settings
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.29 Insider Own0.70% Shs Outstand146.23M Perf Week-4.08%
Market Cap10.27B Forward P/E347.77 EPS next Y0.20 Insider Trans-46.28% Shs Float145.27M Perf Month-1.61%
Income-42.50M PEG- EPS next Q0.04 Inst Own98.00% Short Float3.48% Perf Quarter29.68%
Sales598.10M P/S17.18 EPS this Y-33.30% Inst Trans0.75% Short Ratio4.13 Perf Half Y54.84%
Book/sh9.14 P/B7.69 EPS next Y-25.74% ROA-2.40% Target Price68.60 Perf Year35.67%
Cash/sh3.92 P/C17.94 EPS next 5Y7.10% ROE-3.30% 52W Range38.49 - 74.96 Perf YTD19.96%
Dividend- P/FCF1938.24 EPS past 5Y-38.50% ROI1.90% 52W High-6.28% Beta1.08
Dividend %- Quick Ratio6.90 Sales past 5Y5.80% Gross Margin71.20% 52W Low82.51% ATR2.76
Employees1250 Current Ratio7.40 Sales Q/Q14.40% Oper. Margin-11.00% RSI (14)52.15 Volatility3.86% 3.98%
OptionableYes Debt/Eq0.27 EPS Q/Q-350.00% Profit Margin-7.10% Rel Volume5.07 Prev Close71.23
ShortableYes LT Debt/Eq0.26 EarningsFeb 24 BMO Payout- Avg Volume1.23M Price70.25
Recom2.20 SMA20-1.17% SMA506.14% SMA20035.62% Volume6,215,947 Change-1.38%
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Nov-01-13Reiterated Mizuho Neutral $30 → $33
Oct-30-13Initiated FBR Capital Mkt Perform $31
May-24-13Reiterated UBS Buy $32 → $37
May-24-13Downgrade MKM Partners Neutral → Sell
Apr-18-13Downgrade Mizuho Buy → Neutral $30 → $26
Apr-17-13Reiterated MKM Partners Neutral $23 → $25
Jan-23-13Downgrade MKM Partners Buy → Neutral
Nov-16-12Initiated Mizuho Buy $27
Jan-25-12Upgrade MKM Partners Neutral → Buy $19 → $20
Aug-23-11Upgrade UBS Neutral → Buy $20.50 → $21
Jul-08-11Reiterated UBS Neutral $19 → $20.50
Jun-07-11Reiterated UBS Neutral $16.50 → $19
Feb-26-15 11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Zacks
Feb-25-15 09:32AM  Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Zacks
Feb-24-15 04:00PM  Alkermes Corporate Presentation to be Webcast at the Cowen and Company 35th Annual Health Care Conference Business Wire
12:55PM  Alkermes shares down after it stops development of pain pill at American City Business Journals
11:58AM  Alkermes beats Street 4Q forecasts AP
11:18AM  Jim Cramer: Use Share Weakness to Buy Alkermes for Its Drug Pipeline at TheStreet
10:21AM  Waiting for Yellen Q&A, but QE helping elsewhere at CNBC
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:54AM  Alkermes To Discontinue Development of Pain Treatment at The Wall Street Journal
07:07AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q4 2014 Alkermes Plc Earnings Release - Before Market Open CCBN
07:01AM  Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and Provides Financial Expectations for 2015 Business Wire
07:00AM  Alkermes Announces Results From Phase 1 Study of ALKS 7106 Business Wire
Feb-23-15 04:00PM  Alkermes Announces Webcast of Analyst and Investor Event on March 2, 2015 Business Wire
07:00AM  Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President of Research, Pharmaceutical and Nonclinical Development Business Wire
Feb-17-15 04:00PM  Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results Business Wire
Feb-12-15 09:30AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes - Press Releases Zacks
Feb-11-15 06:00AM  Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS at TheStreet
Feb-10-15 08:35PM  Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News at TheStreet
04:20PM  Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog Zacks
Feb-09-15 07:14AM  Bull targeting Alkermes on pullback optionMONSTER
07:00AM  Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
Feb-03-15 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
Jan-27-15 06:00PM  Cramer: Wouldn't you rather own a winner than a whiner? CNBC
Jan-19-15 09:32AM  Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape Zacks
Jan-14-15 02:37PM  Why Citigroup Placed An $85 Price Target On Shares Of Alkermes Benzinga
Jan-07-15 02:47PM  Schizophrenia breakthrough? CNBC +9.55%
02:19PM  Alkermes stock surges after schizophrenia drug shows effectiveness without weight gain at American City Business Journals
02:10PM  Alkermes schizophrenia drug effective without the weight gain, early data show at bizjournals.com
01:00PM  Midday movers: Alkermes, Lennar, Radian Group & more at CNBC
12:55PM  Jim Cramer Says Alkermes Shares Are Going 'Much Higher' at TheStreet
12:03PM  Alkermes Hits High On Schizophrenia Drug Results at Investor's Business Daily
10:49AM  Alkermes CEO: Our Proprietary Drug Pipeline is 'Maturing Beautifully' at TheStreet
09:55AM  Cramer's Stop Trading: 'Holy Grail' drug CNBC
09:16AM  [$$] Alkermes Schizophrenia Drug Shows Less Weight Gain at The Wall Street Journal
09:06AM  SuperValu, J.C. Penney, Monsanto climb; Micron falls at MarketWatch
08:35AM  Alkermes shares up 5% on news of positive trial for schizophrenia drug at MarketWatch
08:24AM  Alkermes schizophrenia drug meets main goal in mid-stage trial Reuters
07:00AM  Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Business Wire
Jan-06-15 04:00PM  Alkermes Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare Conference Business Wire
12:55PM  Midday movers: Chevron, Hess, Morgan Stanley & more at CNBC
09:55AM  Cramer's Stop Trading: Biotech underestimated CNBC
07:00AM  Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
Dec-15-14 07:00AM  Alkermes Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
Dec-05-14 04:53PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
Nov-25-14 04:02PM  Alkermes Corporate Presentation to be Webcast at The NASDAQ OMX 31st Investor Program Business Wire
Nov-18-14 06:00PM  Cramer shares hazards of skepticism CNBC
Nov-13-14 11:30AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Nov-04-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference Business Wire
Oct-31-14 03:30PM  Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y Zacks
Oct-29-14 10:07AM  Alkermes reports 3Q loss AP
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:11AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q3 2014 Alkermes Plc Earnings Release - Before Market Open CCBN
07:00AM  Alkermes plc Reports Third Quarter 2014 Financial Results Business Wire
Oct-22-14 04:00PM  Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results Business Wire
07:00AM  Alkermes New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA Business Wire
Sep-24-14 06:15PM  Cramer's favorite large cap biotech plays CNBC
09:45AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Sep-16-14 06:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical at TheStreet
Sep-04-14 05:10PM  Alkermes Completes Enrolment for Phase II ALKS 3831 Study Zacks
Sep-03-14 05:14PM  Massachusetts jail offers $1,000-a-shot drug to fight addiction, recidivism Reuters
10:45AM  Credit Suisses 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014 24/7 Wall St.
07:00AM  Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic Business Wire
Sep-02-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-27-14 06:10PM  Alkermes Begins a Study on ALKS7106 for Treatment of Pain Zacks
Aug-26-14 06:00PM  Alkermes Gains on Aripiprazole Lauroxil NDA Submission Zacks
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain Business Wire
Aug-25-14 07:00AM  Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
Aug-08-14 10:25AM  Wall Street Transcript Interview with Howard Zauberman, the President and CEO of Vision-Sciences, Inc. (VSCI) Wall Street Transcript
Aug-04-14 02:40PM  Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up Zacks
Jul-31-14 08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN -7.69%
07:07AM  Q2 2014 Alkermes plc Earnings Release - Before Market Open CCBN
07:05AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports Second Quarter 2014 Financial Results Business Wire
Jul-30-14 07:00AM  Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder Business Wire
Jul-24-14 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Business Wire
Jul-23-14 07:10AM  Is Alkermes plc Stock Undervalued? at Motley Fool
Jul-21-14 03:40PM  Alkermes' Pipeline Development Impresses, Key Updates Ahead Zacks
Jul-17-14 07:05AM  Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS at theflyonthewall.com
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
Jul-09-14 07:00AM  Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Business Wire
Jul-08-14 12:47PM  Momentum names slammed as volatility comes back at CNBC
09:55AM  Why Mylan Should Buy Alkermes at Motley Fool
Jun-23-14 07:04AM  Alkermes plc (ALKS) Jumps: Stock Rises 5.7% Zacks
Jun-20-14 07:00AM  Lundbeck Delivers Some Data-Driven Upside at Seeking Alpha +5.71%
Jun-19-14 10:40AM  Alkermes' Aripiprazole Lauroxil Looks Promising Zacks
Jun-18-14 08:17AM  New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits at Forbes
07:03AM  Alkermes presents aripiprazole lauroxil phase 3 data theflyonthewall.com
07:00AM  Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting Business Wire
Jun-11-14 04:00PM  Alkermes Progresses with its Late Stage Candidate Zacks
Jun-10-14 07:05AM  Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies at theflyonthewall.com
07:00AM  Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
Jun-09-14 02:27PM  What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort at The Wall Street Journal
Jun-06-14 03:30PM  Alkermes' Pipeline Holds Promise Zacks
Jun-05-14 12:00AM  Sanofi, Alkermes Name, Pandora: Intellectual Property at Bloomberg
Jun-03-14 07:00AM  Alkermes to Present Data on New Medicines in Development for Schizophrenia and Depression at Upcoming American Society of Clinical Psychopharmacology Annual Meeting Business Wire
Jun-02-14 07:00AM  Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic Business Wire
May-31-14 12:47AM  [$$] Ivy Mid Cap Growth: Rethinking Risk at Barrons.com
May-28-14 04:53PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur EDGAR Online
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cooke ShanePresident, Alkermes plcFeb 23Option Exercise14.6018,000262,80050,660Feb 23 05:54 PM
Cooke ShanePresident, Alkermes plcFeb 23Sale74.2918,0001,337,30432,660Feb 23 05:54 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Feb 17Option Exercise18.1118,000325,89040,973Feb 18 05:19 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Feb 17Sale70.8718,0001,275,69122,973Feb 18 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcFeb 03Option Exercise9.2110,00092,10087,162Feb 04 05:53 PM
FRATES JAMES MSVP & CFO, Alkermes plcFeb 03Sale70.8310,000708,30677,162Feb 04 05:53 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Feb 02Option Exercise18.1115,000271,57521,639Feb 04 05:49 PM
BREYER ROBERT ADirectorFeb 02Option Exercise14.925,00074,60058,156Feb 04 05:51 PM
BREYER ROBERT ADirectorFeb 02Sale72.915,000364,55053,156Feb 04 05:51 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Feb 02Sale72.0115,0001,080,1096,639Feb 04 05:49 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jan 26Option Exercise18.1115,000271,57521,639Jan 27 06:28 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jan 26Sale70.0215,0001,050,2876,639Jan 27 06:28 PM
Cooke ShanePresident, Alkermes plcJan 23Option Exercise14.60118,0001,722,800150,660Jan 26 06:14 PM
Cooke ShanePresident, Alkermes plcJan 23Sale69.13118,0008,157,23432,660Jan 26 06:14 PM
BLOOM FLOYD EDirectorJan 16Sale67.0716,5001,106,58290,281Jan 20 06:28 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Jan 15Option Exercise18.1218,375332,86541,348Jan 16 05:49 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Jan 15Sale66.4518,3751,221,07122,973Jan 16 05:49 PM
BLOOM FLOYD EDirectorJan 15Sale67.363,500235,750106,781Jan 20 06:28 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Jan 07Option Exercise18.6028,374527,756108,036Jan 08 06:18 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Jan 07Sale65.0028,3741,844,31079,662Jan 08 06:18 PM
BREYER ROBERT ADirectorJan 02Option Exercise14.925,00074,60058,156Jan 05 05:32 PM
BREYER ROBERT ADirectorJan 02Sale58.575,000292,85053,156Jan 05 05:32 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 11Option Exercise14.9050,000745,000570,063Dec 11 06:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 11Sale56.2050,0002,810,050520,063Dec 11 06:01 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 10Option Exercise11.8818,870224,26396,032Dec 11 05:49 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 10Option Exercise14.9050,000745,000570,063Dec 11 06:01 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 10Sale56.0718,8701,057,98477,162Dec 11 05:49 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 10Sale55.8850,0002,794,139520,063Dec 11 06:01 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 09Option Exercise14.9018,000268,200148,521Dec 11 05:41 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 09Sale56.8218,0001,022,809130,521Dec 11 05:41 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Dec 05Option Exercise14.9015,433229,95295,095Dec 05 05:41 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Dec 05Sale57.6115,433889,05679,662Dec 05 05:41 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 03Option Exercise14.908,000119,20085,162Dec 05 05:38 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 03Sale55.728,000445,77877,162Dec 05 05:38 PM
BREYER ROBERT ADirectorDec 01Option Exercise18.295,00091,45058,156Dec 02 05:40 PM
BREYER ROBERT ADirectorDec 01Sale54.645,000273,20053,156Dec 02 05:40 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 26Option Exercise8.5511,696100,00181,479Nov 26 05:20 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 19Option Exercise14.908,000119,20085,162Nov 21 05:09 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 19Sale53.868,000430,89877,162Nov 21 05:09 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Nov 13Option Exercise11.748,51799,99041,044Nov 13 05:12 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 13Option Exercise14.9050,000745,000570,063Nov 13 05:11 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 13Sale52.8850,0002,643,990520,063Nov 13 05:11 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 12Option Exercise14.9050,000745,000570,063Nov 13 05:11 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 12Sale52.8650,0002,643,175520,063Nov 13 05:11 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 11Option Exercise14.9015,000223,500145,521Nov 13 05:08 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 11Option Exercise14.9015,000223,50084,783Nov 13 05:09 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 11Sale52.7415,000791,07569,783Nov 13 05:09 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 11Sale52.7415,000791,121130,521Nov 13 05:08 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 07Option Exercise12.3713,303164,54190,465Nov 07 05:46 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 07Sale49.9813,303664,94477,162Nov 07 05:46 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 06Option Exercise14.9020,000298,00089,783Nov 07 05:42 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 06Sale50.5420,0001,010,72869,783Nov 07 05:42 PM
BREYER ROBERT ADirectorNov 03Option Exercise18.295,00091,45058,156Nov 04 06:02 PM
BREYER ROBERT ADirectorNov 03Sale50.055,000250,25053,156Nov 04 06:02 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 31Option Exercise13.3944,805599,97479,140Nov 04 05:59 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 23Option Exercise16.5514,577241,24947,104Oct 23 05:17 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 23Sale45.0014,577655,96532,527Oct 23 05:17 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 16Option Exercise14.9050,000745,000570,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 16Sale41.1850,0002,058,912520,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 15Option Exercise14.9050,000745,000570,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 15Sale41.0650,0002,053,110520,063Oct 16 05:30 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 14Option Exercise14.9015,000223,500145,521Oct 16 05:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 14Sale40.6515,000609,737130,521Oct 16 05:26 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 08Option Exercise11.7316,000187,60060,225Oct 10 05:20 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 08Sale41.0016,000656,07744,225Oct 10 05:20 PM
Cooke ShanePresident, Alkermes plcOct 05Option Exercise0.0012,500039,160Oct 06 05:35 PM
BREYER ROBERT ADirectorOct 01Option Exercise18.295,00091,45058,156Oct 03 05:06 PM
BREYER ROBERT ADirectorOct 01Sale42.595,000212,95053,156Oct 03 05:06 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 24Option Exercise11.7316,000187,60060,225Sep 24 05:25 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 24Sale45.2916,000724,64044,225Sep 24 05:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 18Option Exercise14.9015,000223,500145,521Sep 19 05:23 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 18Sale45.6015,000684,063130,521Sep 19 05:23 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Option Exercise14.9050,000745,000570,063Sep 19 05:19 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 17Option Exercise15.9114,900237,08647,427Sep 19 05:21 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 17Sale45.0414,900671,04732,527Sep 19 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Sale44.8950,0002,244,585520,063Sep 19 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 10Option Exercise11.7316,000187,60060,225Sep 12 05:05 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 10Sale43.1816,000690,82644,225Sep 12 05:05 PM
MITCHELL PAUL JDirectorSep 02Option Exercise11.841,00011,8409,000Sep 02 05:07 PM
BREYER ROBERT ADirectorSep 02Option Exercise18.295,00091,45058,156Sep 02 05:10 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 02Option Exercise11.741,10012,91433,627Sep 04 05:25 PM
BREYER ROBERT ADirectorSep 02Sale45.125,000225,60053,156Sep 02 05:10 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 02Sale45.081,10049,59232,527Sep 04 05:25 PM
MITCHELL PAUL JDirectorSep 02Sale45.121,00045,1208,000Sep 02 05:07 PM
BLOOM FLOYD EDirectorAug 28Option Exercise16.7720,000335,400110,281Sep 02 05:06 PM